Patents by Inventor Shizuka Ono

Shizuka Ono has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • NOVEL CRYSTAL OF (3S)-3-[2-(6-AMINO-2-FLUOROPYRIDIN-3-YL)-4-FLUORO-1H-IMIDAZOL-5-YL]-7-[5-CHLORO-2-(1H-TETRAZOL-1-YL)PHENYL]-2,3-DIHYDROINDOLIZIN-5(1H)-ONE
    Publication number: 20210395250
    Abstract: A novel crystal form of (3S)-3-[2-(6-amino-2-fluoropyridin-3-yl)-4-fluoro-1H-imidazol-5-yl]-7-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]-2,3-dihydroindolizin-5(1H)-one, which is (3S)-3-[2-(6-amino-2-fluoropyridin-3-yl)-4-fluoro-1H-imidazol-5-yl]-7-[5-chloro-2-(1H-tetrazol-1-yl)phenyl]-2,3-dihydroindolizin-5(1H)-one-3-hydroxybenzoic acid (1/1).
    Type: Application
    Filed: November 29, 2019
    Publication date: December 23, 2021
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Takayuki FUJITO, Shizuka ONO, Shuhei OHTANI
  • Ethane-sulfonate salt of quinoline derivative
    Patent number: 10836747
    Abstract: The present invention relates to an ethane-sulfonate salt of N-{5-[(6,7-dimethoxy-4-quinolinyl)oxy]-2-pyridinyl}-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydro-3-quinolinecarboxamide, which has an Axl-inhibiting activity and is useful as a prophylactic and/or therapeutic agent for immune diseases, cancer and the like, a crystal thereof, and a pharmaceutical composition thereof.
    Type: Grant
    Filed: January 25, 2018
    Date of Patent: November 17, 2020
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Takahiro Nekado, Hideomi Kijima, Shizuka Ono, Toshihiko Nishiyama
  • ETHANE-SULFONATE SALT OF QUINOLINE DERIVATIVE
    Publication number: 20190389837
    Abstract: The present invention relates to an ethane-sulfonate salt of N-{5-[(6,7-dimethoxy-4-quinolinyl)oxy]-2-pyridinyl}-2,5-dioxo-1-phenyl-1,2,5,6,7,8-hexahydro-3-quinolinecarboxamide, which has an Axl-inhibiting activity and is useful as a prophylactic and/or therapeutic agent for immune diseases, cancer and the like, a crystal thereof, and a pharmaceutical composition thereof.
    Type: Application
    Filed: January 25, 2018
    Publication date: December 26, 2019
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Takahiro NEKADO, Hideomi KIJIMA, Shizuka ONO, Toshihiko NISHIYAMA
  • Acid-addition salt of Trk-inhibiting compound
    Patent number: 10399959
    Abstract: In order to provide a prophylactic and/or therapeutic agent for Trk-related diseases, the present invention provides a compound which has a selective Trk-inhibiting activity and persistently inhibits NGF vascular hyper permeability and does not have a drug interaction and in addition thereto, is excellent in solubility and absorbability against free bases. The compound of the present invention has a selective Trk-inhibiting activity and persistently inhibits NGF vascular hyper permeability and does not have a drug interaction and is excellent in solubility and absorbability against free bases, and is therefore useful as a prophylactic and/or therapeutic agent for Trk-related diseases.
    Type: Grant
    Filed: August 17, 2015
    Date of Patent: September 3, 2019
    Assignee: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Jun Takeuchi, Satoshi Itadani, Masahiro Ikura, Masato Higashino, Hideomi Kijima, Shizuka Ono, Tetsuya Yasuhiro, Takeshi Nagaura
  • ACID-ADDITION SALT OF Trk-INHIBITING COMPOUND
    Publication number: 20170240527
    Abstract: In order to provide a prophylactic and/or therapeutic agent for Trk-related diseases, the present invention provides a compound which has a selective Trk-inhibiting activity and persistently inhibits NGF vascular hyper permeability and does not have a drug interaction and in addition thereto, is excellent in solubility and absorbability against free bases. The compound of the present invention has a selective Trk-inhibiting activity and persistently inhibits NGF vascular hyper permeability and does not have a drug interaction and is excellent in solubility and absorbability against free bases, and is therefore useful as a prophylactic and/or therapeutic agent for Trk-related diseases.
    Type: Application
    Filed: August 17, 2015
    Publication date: August 24, 2017
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Jun TAKEUCHI, Satoshi ITADANI, Masahiro IKURA, Masato HIGASHINO, Hideomi KIJIMA, Shizuka ONO, Tetsuya YASUHIRO, Takeshi NAGAURA
  • Crystalline forms of 4, 4?-[4-fluoro-7-({4-[4-(3-fluoro-2-methylphenyl) butoxy] phenyl} ethynyl)-2-methyl-1H-indole-1,3-diyl] dibutanoic acid, 4,4?-[2-methyl-7-({4-[4-(pentafluorophenyl) butoxy] phenyl} ethynyl)-1H-indole-1, 3-diyl] dibutanoic acid, and 4,4?-[4-fluoro-2-methyl-7-({4-[4-(2, 3, 4, 6-tetrafluorophenyl) butoxy] phenyl} ethynyl)-1H-indole-1, 3-diyl] dibutanoic acid
    Patent number: 8598223
    Abstract: The present invention provides type C crystal of compound I, type B crystal of compound II, or type C crystal of compound III set forth in this specification.
    Type: Grant
    Filed: June 20, 2011
    Date of Patent: December 3, 2013
    Assignee: Ono Pharmaceutical Co., Ltd.
    Inventors: Jun Takeuchi, Satoshi Itadani, Junya Ueda, Shizuka Ono, Takahiro Nekado, Manabu Fujita
  • CRYSTALLINE FORMS OF 4, 4'- [4-FLUORO-7-( ETHYNYL)-2-METHYL-1H-INDOLE-1,3-DIYL] DIBUTANOIC ACID, 4,4'-[2-METHYL-7-( ETHYNYL)-1H-INDOLE-1, 3-DIYL] DIBUTANOIC ACID, AND 4,4'-[4-FLUORO-2-METHYL-7- ( ETHYNYL)-1H-INDOLE-1, 3-DIYL] DIBUTANOIC ACID
    Publication number: 20130090482
    Abstract: The present invention provides type C crystal of compound I, type B crystal of compound II, or type C crystal of compound III set forth in this specification.
    Type: Application
    Filed: June 20, 2011
    Publication date: April 11, 2013
    Applicant: ONO PHARMACEUTICAL CO., LTD.
    Inventors: Jun Takeuchi, Satoshi Itadani, Junya Ueda, Shizuka Ono, Takahiro Nekado, Manabu Fujita